October 2015 | HCC Monitor

Novel Immunotherapies on the Horizon in HCC

October 10, 2015

Clinical Articles

In recent years, knowledge of hepatocellular carcinoma (HCC)-specific tumor-associated antigens and the development of immune checkpoint blockade therapy has offered a positive outlook for patients with HCC.

Role of MicroRNAs Evolving in the Diagnosis and Treatment of HCC

October 12, 2015

Clinical Articles

Hepatocellular carcinoma has traditionally been an aggressive malignancy, with diagnosis taking place at later stages of disease and a poor prognosis in most patients. However, recent advances in molecular diagnostics and treatment show promise in changing the HCC clinical landscape.

Second-Line Treatments for Advanced Hepatocellular Carcinoma

October 13, 2015

Clinical Articles

No established regimens exist for the treatment of patients with advanced hepatocellular carcinoma after failure of first-line treatment with the multikinase inhibitor sorafenib. Outcomes in the setting of sorafenib resistance or intolerance are poor, with a median expected overall survival for the placebo arms of second-line trials in the range of 7 to 8 months.

Tivantinib Biomarker Analysis Validates Phase III Design

October 14, 2015

Clinical Articles

Treatment with tivantinib has proven highly effective in patients with hepatocellular carcinoma and with high MET expression, suggesting a prognostic and predictive biomarker of response.

Monitoring Circulating Tumor DNA Could Improve Outcomes in HCC

October 15, 2015

Clinical Articles

The presence of circulating tumor DNA in serum could predict microscopic vascular invasion of the portal vein and extrahepatic metastasis following surgery for patients with hepatocellular carcinoma.

CF102 Receives Fast Track Designation for HCC

October 15, 2015

Clinical Articles

The FDA has granted the A3AR agonist CF102 a fast track designation as a second-line treatment for patients with hepatocellular carcinoma. The drug is also planned to be tested in patients with rheumatoid arthritis and psoriasis.